Clinical trial
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently…
NCT00160992 · University of Lausanne Hospitals, Other · Suspended
Key facts
| NCT number | NCT00160992 |
|---|---|
| Title | Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients |
| Official title | Phase I Study of in Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma |
| Lead sponsor | University of Lausanne Hospitals, Other |
| Collaborators | Fond'action contre le cancer Barletta Foundation NCCR (National Center of Competence in Resaerch, Switzerland) |
| Status | Suspended |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Melan-A analog peptide |
| Enrollment | 6 |
| Start date | Jul 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Sep 12, 2005 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: